SCHEMBL20833799

SCHEMBL20833799

Cc1cccc(Cl)c1-n1ncc(C2CC2)c1CCl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.36
KCNJ5 P48544 1/20 0.34
KCNJ3 P48549 1/20 0.34
GRM2 Q14416 3/20 0.33
OPRM1 P35372 2/20 0.32
OPRL1 P41146 2/20 0.32
TP53 P04637 2/20 0.32
WEE1 P30291 1/20 0.32
ALDH1A1 P00352 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LMNA P02545 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
DHODH Q02127 1/20 0.31
P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30807047 1.00 NR1H4 (0.36) NR1H4KCNJ5KCNJ3GRM2OPRM1
SCHEMBL20833979 0.92 TP53 (0.36) GRM2TP53ALDH1A1NPC1RAB9A
SCHEMBL17839932 0.91 NR1H4 (0.41) NR1H4KCNJ5KCNJ3GRM2ALDH1A1
SCHEMBL20833875 0.89 NR1H4 (0.38) NR1H4KCNJ5KCNJ3OPRM1OPRL1
SCHEMBL20833800 0.89 NR1H4 (0.36) NR1H4KCNJ5KCNJ3GRM2OPRM1
SCHEMBL30034762 0.89 NR1H4 (0.36) NR1H4KCNJ5KCNJ3GRM2OPRM1
SCHEMBL20833739 0.85 NR1H4 (0.42) NR1H4GRM2OPRL1DHODH
SCHEMBL1097296 0.79 NR1H4 (0.40) NR1H4KCNJ5KCNJ3GRM2ALDH1A1
SCHEMBL20833733 0.79 NR1H4 (0.40) NR1H4KCNJ5KCNJ3GRM2ALDH1A1
SCHEMBL1095874 0.79 NR1H4 (0.42) NR1H4KCNJ5KCNJ3GRM2WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753410-B2 Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders ARDELYX, INC. (US) 2023-09-12 US disclosed
US-11753410-B2 Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders ARDELYX, INC. (US) 2023-09-12 US disclosed
US-11753410-B2 Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders ARDELYX, INC. (US) 2023-09-12 US disclosed
EP-3681881-B1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS ARDELYX INC (US) 2022-11-02 EP disclosed
US-20210380585-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2021-12-09 US disclosed
WO-2019055808-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380585-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS NR1H4, FXR1, FXR2 NR1H4 1/4885KCNJ5 3874/4885KCNJ3 3211/4885
US-11753410-B2 Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders NR1H4, FXR1, FXR2 NR1H4 1/4885KCNJ5 3874/4885KCNJ3 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.